Journal of Postgraduate Medicine, Education and Research

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  58 (2024)
Volume  57 (2023)
Volume  56 (2022)
Volume  55 (2021)
Volume  54 (2020)
Volume  53 (2019)
Volume  52 (2018)
Volume  51 (2017)
Volume  50 (2016)
Volume  49 (2015)
Volume  48 (2014)
Volume  47 (2013)
Volume  46 (2012)
Related articles

VOLUME 47 , ISSUE 4 ( October-December, 2013 ) > List of Articles

REVIEW ARTICLE

Tuberculosis and Nanotechnology: Where shall the Twain meet?

Ritika Kondel

Citation Information : Kondel R. Tuberculosis and Nanotechnology: Where shall the Twain meet?. J Postgrad Med Edu Res 2013; 47 (4):188-192.

DOI: 10.5005/jp-journals-10028-1084

Published Online: 01-09-2015

Copyright Statement:  Copyright © 2013; The Author(s).


Abstract

How to cite this article

Shafiq N, Kondel R, Malhotra S. Tuberculosis and Nanotechnology: Where shall the Twain meet? J Postgrad Med Edu Res 2013;47(4):188-192.

PDF Share
  1. Global tuberculosis control: a short update to the 2009 report. WHO/HTM/TB/2009426. Geneva: World Health Organization 2009. Available at: http://whqlibdoc.who.int/publications/2009/9789241598866_eng.pdf (accessed July 1, 2010).
  2. Prevalence of multidrug resistance in Mycobacterium tuberculosis isolates from HIV seropositive and seronegative patients with pulmonary tuberculosis in north India. BMC Infect Dis 2013 Mar 15;13:137
  3. Priorities for tuberculosis research: a systematic review. Lancet Infect Dis 2010 Dec; 10(12):886-889.
  4. Tuberculosis research and development: a critical analysis of funding trends 2005–2007—an update. New York: Treatment Action Group, 2009 March. Available at: http://www.Treatmentactiongroup.org/uploadedFiles/About/Publications/TAG_Publications/2009/TAG%20TB%202009%20webversion2.pdf (accessed July 1, 2010).
  5. Nanosuspension: an approach to enhance solubility of drugs. J Adv Pharm Technol Res 2011 Apr;2(2):81-87.
  6. Current state of nanoemulsions in drug delivery. JBNB 2011;2:629-639.
  7. Nonionic surfactant based vesicles (niosomes) in drug delivery. International J Pharmaceutics 1998 Oct;172(1-2):33-70.
  8. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 2001 Jan 29;70(1-2):1–20.
  9. Nonpolymeric nanoparticles for photodynamic therapy applications: recent developments. Curr Med Chem 2012;19(6):781-792.
  10. Drug-loaded PLGA nanoparticles for oral administration: fundamental issues and challenges ahead. Crit Rev Ther Drug Carrier Syst 2012;29:149-182.
  11. Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery styem against murine tuberculosis. Tuberculosis 2003; 83:373-378.
  12. Chemotherapeutic efficacy of poly (DL-lactide-co-glycolide) nanoparticle encapsulated antitubercular drugs at sub-therapeutic dose against experimental tuberculosis. Int J Antimicrob Agents 2004;24: 599-604.
  13. The potential advantages of nanoparticles drug delivery systems in chemotherapy of tuberculosis. Am J Resp Crit Care Med 2005; 172:1487-1490.
  14. In vitro physicochemical characterization and short term in vivo tolerability study of ethionamide loaded PLGA nanoparticles: potentially effective agent for multidrug resistant tuberculosis. J Microencapsul 2011;28(8):717-728.
  15. Optimization, in vitro in vivo evaluation, and short-term tolerability of novel levofloxacin-loaded PLGA nanoparticle formulation. J Pharm Sci 2012 Jun;101(6):2165-2176.
  16. Polylactide-co-glycolide rifampicin nanoparticles efficiently clear Mycobacterium bovis BCG infection in macrophages and remain membrane-bound in phago-lysosomes. J Cell Sci 2013 July 15;126(pt 14):3043–3054.
  17. Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. Int J Antimicrob Agents 2005;26:298-303.
  18. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis 2005;85:227-234.
  19. Ocular signs predictive of tubercular uveitis. Am J Ophthalmol 2010; 149:562-570.
  20. Continuous progression of tubercular serpiginous-like choroiditis after initiating antituberculosis treatment. Am J Ophthalmol 2011;152:857-863.
  21. Intraocular tuberculosis—an update. Surv Ophthalmol 2007;52:561-587.
  22. Nanoparticle based adjuvant for enhanced protective efficacy of DNA vaccine Ag85A-ESAT-6- IL-21 against Mycobacterium tuberculosis infection. Nanomedicine 2012;8:1337-1344.
  23. Pulmonary delivery of DNA encoding Mycobacterium tuberculosis latency antigen RV1733C associated to PLGA-PE1 nanoparticles enhances T cell response in a DNA prime/protein boost vaccination regimen in mice. Vaccine 2009;27:4010-4017.
  24. Enhanced immune response and protective effects of nano-chitosan-based DNA vaccine encoding T cell epitopes of Esat-6 and FL against Mycobacterium tuberculosis infection. PLo S One 2013 Apr 23;8(4):e61135
  25. Vaccine delivery system for tuberculosis based on nano-sized hepatitis B virus core protein particles. Int J Nanomedicine 2013;8:835-843.
  26. Rapid amplification for the detection of Mycobacterium tuberculosis using a non-contact heating method in a silicon microreactor based thermal cycler. Sensors and Actuators B 2004;102:308-314.
  27. Chip-NMR biosensor for detection and molecular analysis of cells. Nat Med 2008;14:869-874.
  28. Unmodified gold nanoparticles for direct and rapid detection of Mycobacterium tuberculosis complex. Clin Biochem 2013 May;46(7-8):633-637.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.